BioNexus Becomes First Nasdaq Firm to Adopt Ethereum-Focused Treasury Strategy

BioNexus Gene Lab Corporation has officially approved an Ethereum-focused treasury strategy, marking it as the first Nasdaq-listed company to exclusively prioritize Ethereum as a strategic asset.

The Wyoming-based tech firm announced the decision Wednesday, alongside the release of its Ethereum Strategy Whitepaper, which outlines its reasoning for choosing Ethereum over Bitcoin for corporate treasury management.

"While Bitcoin remains a strong store of value, Ethereum provides broader utility as a programmable financial platform," the company stated in its whitepaper.

One of Ethereum’s key advantages, according to BioNexus, is its ability to generate yield through staking—something Bitcoin does not offer despite its increasing adoption by institutional investors.

"Unlike Bitcoin, Ethereum provides an additional revenue stream through staking. Ethereum's Proof-of-Stake mechanism allows holders to generate 3-5% annual yield," the firm noted, adding that this capability has the potential to transform Ethereum "from a passive asset into an income-generating treasury instrument."

BioNexus also emphasized Ethereum's growing institutional acceptance, pointing to its adoption by major financial players like BlackRock and Fidelity. This, the company argues, validates Ethereum’s "long-term potential as a financial instrument."

"Our goal is to strategically position Ethereum as a core component of our treasury over time," BioNexus CEO Sam Tan told Decrypt. "I can confirm that our Board’s approval provides flexibility. We intend to allocate a meaningful portion of our reserves to Ethereum."

"We’re currently weighing whether to operate our own validator nodes or partner with established third-party staking providers," Tan explained. "Our choice will hinge on security, efficiency, and compliance, and we’ll finalize this as we scale our Ethereum holdings."

The company also highlighted Ethereum’s crucial role in the financial ecosystem, citing its use as the settlement layer for stablecoins like USDT and USDC, which process trillions of dollars in transactions annually.

Furthermore, BioNexus referenced Ethereum’s upcoming Pectra protocol upgrade, viewing it as a development that could further solidify Ethereum’s position as "a dependable long-term infrastructure for businesses."

However, the Pectra update has encountered challenges, including recent issues during its Sepolia testnet deployment on Wednesday, following previous setbacks in the Holesky testing phase.

BioNexus' Financial Challenges and Compliance Hurdles

While BioNexus is embracing Ethereum for its treasury, the company is also grappling with financial difficulties.

Operating primarily in Asia through its Malaysian subsidiary, BioNexus generates 90% of its revenue from industrial chemical supplies for the automotive and aerospace sectors. The remaining 10% comes from its work in genomic diagnostics, including RNA-based blood tests for early cancer and inflammatory disease detection.

Despite these operations, BioNexus has faced financial setbacks. In December 2023, the company received a Nasdaq non-compliance notice for failing to meet the $1 minimum bid price rule. A temporary exception has been granted, giving the firm until May 1, 2025, to regain compliance.

To address this, BioNexus has planned a reverse stock split by April 7, 2025.

Currently, the company reports $9.26 million in trailing twelve-month revenue, with a $5.88 million market cap. Its stock price sits at $0.32, down 61% year-over-year, according to Financial Times data.